Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ARD-2128 is a highly potent, orally bioavailable PROTAC (proteolysis-targeting chimera) degrader of the androgen receptor (AR), effectively diminishing AR protein levels, suppressing AR-regulated gene expression in tumor tissues, and inhibiting tumor growth without evident toxicity. This compound holds promise for prostate cancer research.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 228.00 | |
2 mg | In stock | $ 342.00 | |
5 mg | In stock | $ 578.00 | |
10 mg | In stock | $ 833.00 | |
25 mg | In stock | $ 1,270.00 | |
50 mg | In stock | $ 1,690.00 | |
100 mg | In stock | $ 2,290.00 |
Description | ARD-2128 is a highly potent, orally bioavailable PROTAC (proteolysis-targeting chimera) degrader of the androgen receptor (AR), effectively diminishing AR protein levels, suppressing AR-regulated gene expression in tumor tissues, and inhibiting tumor growth without evident toxicity. This compound holds promise for prostate cancer research. |
Targets&IC50 | LNCaP cells:5 μM (IC50), VCaP:4 nM (IC50) |
In vitro | ARD-2128 exhibits high potency and efficacy in suppressing the growth of both VCaP and LNCaP cell lines, with IC50 values of 4 nM and 5 nM, respectively [1]. Notably, in the VCaP cell line treated with ARD-2128 at concentrations of 1, 10, 100, and 1000 nM for 24 hours, there is a significant decrease in AR protein levels, with reductions of more than 50% observed at 1 nM and over 90% degradation at concentrations of 10, 100, and 1000 nM [1]. This finding is further corroborated by a Cell Viability Assay [1], which demonstrates that ARD-2128 effectively diminishes AR protein levels and facilitates AR degradation in the VCaP cell line under the specified conditions. |
In vivo | ARD-2128 administered orally at a dosage of 20 mg/kg effectively lowers AR protein levels in mice within 24 hours, as per reference [1]. When given daily at doses ranging from 10 to 40 mg/kg for 21 days, the compound demonstrates notable antitumor effects in the VCaP xenograft mouse model, inhibiting tumor growth by 46% to 69% [1]. Pharmacokinetic analysis reveals that a 5 mg/kg oral dosage yields a maximum concentration (C max) of 1304 ng/mL, an area under the curve (AUC 0-t) of 22361 ng h/mL, and a half-life (t 1/2) of 18.8 hours [1]. The study, using SCID and Male ICR mice, indicates that ARD-2128, with oral bioavailability of 67%, effectively reduces AR protein levels and suppresses AR-regulated gene activity in tumor tissues. It thus inhibits tumor growth in mice without observable toxicity. |
Molecular Weight | 820.37 |
Formula | C45H50ClN7O6 |
CAS No. | 2222111-87-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (121.90 mM), Sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
ARD-2128 2222111-87-5 Endocrinology/Hormones Androgen Receptor orally AR-regulated bioavailable inhibit Inhibitor prostate ARD2128 cancer tumor ARD 2128 PROTACs inhibitor